Anzeige
Mehr »
Freitag, 04.07.2025 - Börsentäglich über 12.000 News
+210 % Kursgewinn Year to Date: Neuausrichtung nimmt Fahrt auf - jetzt exklusives CEO-Interview ansehen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
64 Leser
Artikel bewerten:
(0)

Dolcas-Tenshi Bioceuticals Targets Sexual Health with All-natural Fortiquin Botanical Formula

Fortiquin Boosts Men's Sexual Performance Naturally

LANDING, New Jersey, April 16, 2019 /PRNewswire/ -- The new joint venture, DolCas-Tenshi Bioceuticals Inc., is targeting male sexual health in its debut nutraceutical formula, marketed under the name Fortiquin. This five-ingredient, patent-pending blend of herbal extracts and nutrients has been carefully designed to support sexual stamina and overall wellbeing in healthy men experiencing problems with sexual performance. The company will launch the all-natural, vegan complex at Vitafoods Europe in Geneva on May 7-9, 2018, booth F200.

Dolcas-Tenshi Bioceuticals targets sexual health with all-natural Fortiquin botanical formula

Derived from the wisdom of the Ayurvedic medical tradition, Fortiquin is composed of four botanicals: mucuna, cynara, trigonella and ashwanghanda, combined with the amino acid L-arginine. The proprietary blend of natural ingredients works in synergy to nourish and balance multiple systems for the overall enhancement of men's health and, more specifically, sexual stamina. Comprehensive clinical studies are ongoing.

The symbiotic blend of extracts, in proprietary ratios, are standardized to their bioflavonoid and saponin contents. These two classes of phytochemicals are commonly touted for their therapeutic activity, including their effects on the reproductive, vascular and nervous systems.

"Fortiquin is an all-natural powerhouse blend of botanicals," says Shavon Jackson-Michel, ND, Director of Medical and Scientific Affairs for DolCas-Tenshi. "The individual herbs coexist as clean-label extracts, rather than powders, delivering not only an enriched profile of the phytochemicals most associated with their functionality and organ affinity, but also ensuring consistent quality from batch to batch."

"DolCas-Tenshi is attentive to the drive for increased standardization of quality for all aspects of developing natural sexual health products," adds Vivek A. Parachur, co-founder and CEO of Olene Life Sciences, developer and manufacturer of Fortiquin. "This encompasses sourcing, storage, and proper clinical assessment of bioactivity and efficacy. Lack of such attention can leave the consumer with little confidence in product effectiveness. Pursuing the highest level of consumer confidence in the product is where Fortiquin stands out."

The supplement market for sexual performance aids is projected to grow exponentially into 2021. Technavio Research forecasts a steady annual growth rate of about 12% over the 5 year period, with a projected market value of about $376 million[i].

Several factors are driving the expansion of this dynamic niche market. Evolvement of societal perceptions and norms regarding sexual intimacy is eliciting increased customer acceptance of sexual enhancement supplements. Additionally, the anonymity and convenience of internet shopping appears to encourage increased e-commerce activity within this sector.

The potential for Fortiquin is vast. The release of the publication proving its clinical effects on sexual function in men is expected in the late spring of this year. The uniqueness of Fortiquin's composition potentially avails it to other clinical functions, such as sports performance and menopausal support. Dolcas-Tenshi plans to further investigate Fortiquin's applicability for these additional health areas.

Visit us at Vitafoods 2019 in Geneva, booth F200

For more information, contact:

Company contact:
DolCas Biotech, LLC
Dr. Shavon Jackson-Michel
Director of Medical & Scientific Affairs
Tel: 973-347-1958 ext. 217
Email: Info@DTBioceuticals.com
Web: www.dtbioceuticals.com

Press Contact:
NutriPR
Liat Simha
Tel: +972-9-9742893
E-mail: liat@nutripr.com
Website: www.nutripr.com
Twitter: @LiatSimha

Reference:[i]https://www.businesswire.com/news/home/20170426005938/en/Sexual-Enhancement-Supplements-Market---Trends-Forecasts

Photo: https://mma.prnewswire.com/media/872502/DolCas_Fortiquin.jpg

© 2019 PR Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.